Vora N A, Gupta R, Thomas A J, Horowitz M B, Tayal A H, Hammer M D, Uchino K, Wechsler L R, Jovin T G
Department of Neurology, Stroke Institute, University of Pittsburgh, Medical Center, Pittsburgh, PA 15213, USA.
AJNR Am J Neuroradiol. 2007 Aug;28(7):1391-4. doi: 10.3174/ajnr.A0575.
We sought to find predictors for hemorrhagic complications in patients with acute ischemic stroke treated with multimodal endovascular therapy.
We retrospectively reviewed patients with acute ischemic stroke treated with multimodal endovascular therapy from May 1999 to March 2006. We reviewed clinical and angiographic data, admission CT Alberta Stroke Programme Early CT Score (ASPECTS), and the therapeutic endovascular interventions used. Posttreatment CT scans were reviewed for the presence of a parenchymal hematoma or hemorrhagic infarction based on defined criteria. Predictors for these types of hemorrhages were determined by logistic regression analysis.
We identified 185 patients with a mean age of 65+/-13 years and mean National Institutes of Health Stroke Scale score of 17+/-4. Sixty-nine patients (37%) developed postprocedural hemorrhages: 24 (13%) parenchymal hematomas and 45 (24%) hemorrhagic infarctions. Patients with tandem occlusions (odds ratio [OR] 4.6 [1.4-6.5], P<.016), hyperglycemia (OR 2.8 [1.1-7.7], P<.043), or treated concomitantly with intravenous (IV) tissue plasminogen activator (tPA) and intra-arterial (IA) urokinase (OR 5.1 [1.1-25.0], P<.041) were at a significant risk for a parenchymal hematoma. Hemorrhagic infarction occurred significantly more in patients presenting with an ASPECTS<or=7 (OR 1.9 [1.3-2.7], P<.01).
Hemorrhagic infarctions are related to the extent of infarct based on presentation CT, whereas parenchymal hematomas are associated with the presence of tandem occlusions, hyperglycemia, and treatment with both IV tPA and IA urokinase in patients with acute stroke treated with multimodal endovascular therapy.
我们试图找出接受多模式血管内治疗的急性缺血性脑卒中患者出血并发症的预测因素。
我们回顾性分析了1999年5月至2006年3月期间接受多模式血管内治疗的急性缺血性脑卒中患者。我们审查了临床和血管造影数据、入院时CT的阿尔伯塔卒中项目早期CT评分(ASPECTS)以及所采用的治疗性血管内干预措施。根据既定标准,对治疗后的CT扫描进行审查,以确定是否存在脑实质血肿或出血性梗死。通过逻辑回归分析确定这些类型出血的预测因素。
我们确定了185例患者,平均年龄为65±13岁,美国国立卫生研究院卒中量表平均评分为17±4。69例患者(37%)出现术后出血:24例(13%)为脑实质血肿,45例(24%)为出血性梗死。串联闭塞患者(优势比[OR]4.6[1.4 - 6.5],P<0.016)、高血糖患者(OR 2.8[1.1 - 7.7],P<0.043)或同时接受静脉注射(IV)组织纤溶酶原激活剂(tPA)和动脉内(IA)尿激酶治疗的患者(OR 5.1[1.1 - 25.0],P<0.041)发生脑实质血肿的风险显著增加。ASPECTS≤7的患者出血性梗死发生率显著更高(OR 1.9[1.3 - 2.7],P<0.01)。
在接受多模式血管内治疗的急性脑卒中患者中,出血性梗死与基于初始CT的梗死范围有关,而脑实质血肿与串联闭塞、高血糖以及同时接受IV tPA和IA尿激酶治疗有关。